Mylan nabs exclusive Sovaldi, Harvoni deal in India; Bidvest bids $515M for full control of Adcock; Novo sees up to $335M from NNIT spinoff;

Medicine

@FiercePharma: Brain cancer therapy pioneered in dogs wins NCI grant for human development. More | Follow @FiercePharma

@CarlyHFierce: Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash. Release | Follow @CarlyHFierce

> U.S.-based Mylan ($MYL) signed up with Gilead Sciences ($GILD) as its exclusive distributor for branded hepatitis C drugs Sovaldi and Harvoni in India; Mylan was already one of the drugmakers licensed to sell generic versions of the meds. Release

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

> South African conglomerate Bidvest has offered about $515 million to gain full control of drugmaker Adcock Ingram; it currently owns a 34.5% stake in the generics maker. Report

> Novo Nordisk ($NVO) says it expects to rake in up to 2.2 billion kroner ($335 million) in a public stock offering for 40% of its technology subsidiary, NNIT, at 100 to 120 kroner per share. Report

> Pfizer ($PFE) says the FDA accepted its application for a new use for Rapamune (sirolimus), its transplant drug, to treat a rare, often fatal lung disease, lymphangioleiomyomatosis. Release

> Japanese regulators slapped Gilead Sciences for failing to report side effects of three drugs awaiting approval in that country, but already on the market elsewhere. Report

Medical Device News

@FierceMedDev: J&J readies to rid itself of Cordis--for as much as $2B to Cardinal Health. More | Follow @FierceMedDev

@VarunSaxena2: Reg. standards may be for NGS materials, methods & performance. Specific for each area (oncology, germline mutations etc) #PrecisionMedicine. | Follow @VarunSaxena2

@EmilyWFierce: Bayer feels sting of mixed decision from NICE for Eylea's use in diabetics. Article | Follow @EmilyWFierce

> First adhesive varicose vein treatment wins FDA approval. More

> Advisory panel recommends FDA approval of VertiFlex's spinal implant. Story

Biotech News

@FierceBiotech: Merck KGaA carves into MS R&D after a string of setbacks. Story | Follow @FierceBiotech

@JohnCFierce: $LLY, that wunderkind of drug R&D, delays peglispro after all and Tim Anderson sounds taps. Release | Follow @JohnCFierce

@DamianFierce: Big day for Tularik expats, particularly the ones at Flexus and NGM. Story | Report | Follow @DamianFierce

> Celldex jumps after gaining an FDA 'breakthrough.' More

> Bristol-Myers bags IDO immunotherapy in $1.25B buyout of fledgling Flexus. Article

Biotech IT News

> AstraZeneca picks Labguru to improve collaborations with academia. More

> FDA puts cloud storage and Google-esque search tools on precision medicine road map. Story

> Big Data digging yields unprecedented road map of the epigenome. Article

> BGI investor: It is the database they are building that will make them formidable. Report

> Transcriptic snags $8.5M to add capabilities at robot-run lab. News

CRO News

> LabCorp seals its $6B deal for Covance. Article

> After a $300M IPO, PRA forecasts a big 2015. More

> Theorem partners up for patient testing. Report

> Parexel stretches out its site network to speed up enrollment. Story

> WuXi borrows $165M to bankroll more M&A. Item

Animal Health News

> Jaguar posts positive trial results on lead prescription drug for dogs. Item

> Patterson misses on sales and earnings but reaffirms fiscal 2015 guidance. Report

> Australia's Integrated Animal Health to open offices in U.S. Story

> Brain cancer therapy pioneered in dogs wins NCI grant for human development. News

> Dogs get pulled into the medical marijuana debate. Article

And Finally... The U.S. military's health plans spent $84 million on erectile dysfunction meds last year for its beneficiaries, including active-duty personnel, retirees and eligible family members. Report

Read more on

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.